Proteomics insights
With proteomics technologies you can accelerate biological innovation and improve understanding of clinical presentationsProteomics insights
Proteomics offers a holistic view of cellular processes by analyzing the entire set of proteins expressed in a sample, providing valuable insights into disease mechanisms and therapeutic targets.
While genomics provides information on genetic variations, proteomics offers insights into the functional consequences of these variations and their subsequent biological processing at the protein level, bridging the gap between genotype and phenotype.
Tailored proteomics solutions can significantly enhance the efficiency, effectiveness, and success rate of drug discovery and development efforts in the pharmaceutical industry such as:
Biomarker Discovery phase
Proteomic profiling enables the discovery and validation of protein biomarkers for disease diagnosis, prognosis, and monitoring treatment response, supporting clinical decision-making and patient stratification in clinical trials.
Translational research phase
This process accelerates drug discovery and advances translational research by providing crucial insights into target characterization, biomarker validation, patient profiling, and drug screening.
Precision Medicine
Using proteomics, unique patient or disease subpopulations are characterized for tailored therapies. Pre-testing in vitro enables more personalized treatment and monitoring, advancing precision medicine.
Biopharma HCP monitoring
Proteomics analysis demonstrates product risks, safety, and regulatory compliance. It ensures biological purity, optimal efficacy, and production optimization during early stages and clinical trials.
The Human proteoform
Many diseases have an impact on the human proteome, and most drug targets are proteins. The cellular processing of these protein biomarkers into different proteoforms with and without modifications (e.g. glycosylation and other post translational modifications (PTMs)) are needed to understand and follow disease progression.
For example, phosphorylation of proteins associated with neurodegenerative diseases is believed to accelerate protein aggregate formation in the brain. LC-MS based proteomics provides the toolset to measure protein identities, abundances and their modifications.
Proteomics Method Considerations
The two major options for proteomics analysis involve either the traditional Antibody-based methods or Mass Spectrometry (MS)-based methods. Antibody techniques use affinity for specific protein targets or a panel of protein targets to detect and quantify the amount of the set proteins in the panel contained in a sample.
Mass Spectrometry on the other hand, detects in a less biased manner all the protein components present commonly in the form of peptides including any modifications from downstream cellular processing. Combining this with Liquid Chromatography (LC) methods that enable selection of proteome depth requirement or sample complexity, and/or workflows for enrichment of specific proteins of interest, LC-MS based proteomics has become the gold standard technique in proteomics.
The Power of LCMS
By leveraging the power of LC-MS you can effectively separate, identify, and quantify proteins and peptides with exceptional sensitivity and specificity. The advantages include:
-
Simultaneous analysis of multiple proteins without specific antibodies
-
Tunable proteome depth via chromatography methods
-
Confidence in global proteome detection, including low-abundance proteins
-
Flexibility to study protein dynamics and modifications
- Focus on targeted peptides of interest
-
Potential for biomarker discovery and personalized medicine applications
How can you benefit from proteomics?
A biologist, analytical chemist or biological scientist working with biological sample can gain insight into their system of study using proteomic analyses. In many cases expression proteomics is complementary to other Omics technologies such as genomics, transcriptomics and metabolomics as a key link between the genomic data and the phenotype at a specific moment in time.
- Identify disease proteins for biomarkers and prognosis.
- Detect pre-symptomatic protein changes.
- Investigate drug effects and impurities.
- Personalize therapy for patients.
- Characterize host cell proteins for safety.
It is critical in the understanding and monitoring of biological processes, and specifically for pharmaceutical development, how such cells and biological processes are impacted by disease or the introduction of a novel therapeutic agent.
A powerful toolset
By embracing proteomics you gain access to a powerful toolset for advancing drug discovery and biomarker discovery as well as fundamental biological research.
Traditionally LC-MS based proteomics has been the domain of experts, but since the breakthrough in usability and robustness of the Evotip workflow and chromatographic separation the benefits from an unbiased proteome can be experienced by a wider group of clinical researchers and biological scientists.
Evosep One makes it easy
At Evosep, our goal is to empower researchers and clinicians with innovative technology that streamline sample analysis, technology that streamlines sample analysis, is easy to use, and ensures reproducible results. We aim to simplify proteomics workflows and make advanced analytical techniques more accessible to all levels of users.
- Ease of use reduces technical barriers
- Standardization ensures consistency
- Reliability and robustness provide confidence in results
- High throughput capabilities streamline research processes
The Evosep One makes it easy to get started with proteomics analysis, no matter your level of technical experience. With its simple design and standardized methods, you get a liquid chromatography platform built for standardization that enables routine analysis of single samples up to hundreds of proteomes per instrument per day.
What is already being done
We are very proud of what our users have already achieved in this field; some inspiration:
Plasma proteomics
The Centre for Translational Biomedical Research in the University of North Carolina developed an optimized platform with a full workflow they consider promising to support quick and reliable analysis for various clinical medicine needs.
Visit our application page to learn more
Protein Biomarkers
The Liver Research Centre, Odense University Hospital, Odense, Denmark and their collaborators elucidated the pathological features of Alcohol-related liver disease and both discovered and validated plasma biomarkers associated with diagnosis and prognosis in independent cohorts.
Host cell protein
Merck researchers in the USA developed a method overcoming the dynamic range challenges of host cell protein analysis, improving both the number of HCPs relative to previous methods as well as achieving higher throughput and reduced carryover
Visit our application page to learn more
Targeted proteomics
A specific protein of interest with and without mutation was quantified in both frozen and FFPE fixed animal tumor tissue samples using a targeted method which allowed Astrazeneca researchers to determine drug target engagement without protein enrichment or isolation.
Visit our application page to learn more
Immunopeptidomics
Scientists at the Max Planck Institute of Biochemistry, Martinsried, Germany discovered organ-specific HLA peptide patterns in plasma. In the 5000 peptides detected from 200µL plasma samples multiple tissues including the brain were represented.
For more information visit our application page
Targeted Protein Degraders
Molecular Genetics at the University of Toronto, Donnelly Centre and a research group at Mount Sinai Hospital collaborated to develop a platform for identifying proteins that can promote degradation. They found novel degraders that were more potent against multiple therapeutically relevant targets.
Visit our application page to learn more
THE POTENTIAL OF CLINICAL PROTEOMICS
Our pursuit for progress within the proteomics community is fueled by the realization that for mass spectrometry to be an everyday tool in clinical settings, it must not only deliver exceptional performance but also operate with unmatched reliability.
By providing user-friendly workflows and automated processes, we empower researchers without extensive expertise to confidently utilize mass spectrometry in their work. This inclusivity promotes collaborative efforts within the scientific community, encouraging a diverse range of perspectives and accelerating progress in clinical proteomics.
Need more information? We got you covered.
Our team is ready to answer any question you might have about our products. Fill out our contact form and we will get back to you as soon as possible.
